ITP Therapeutics Market is Expected to Reach USD 566.37 million by 2020: Radiant Insights, Inc

Global ITP therapeutics market is expected to reach USD 566.37 million by 2020. Introduction of new drugs especially pertaining to TPO-RA and IVIG classes is expected to serve this market as a high impact rendering driver. Presence of favorable government regulations such as the Orphan Drug Act in the U.S. aimed at encouraging new product development is expected to have a positive impact on the market. Most notable trend observed in this market is an increase in demand for combination therapies involving two or more drugs. Clinical evidences suggest that some combination therapies prove to be cost effective, exhibit higher efficacies and help curb side effects otherwise associated with individual therapeutic classes.

Corticosteroids are the most frequently administered therapy for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids are considered as the first line of treatment in patients with ITP and therefore, enjoy very high usage rates.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/idiopathic-thrombocytopenic-purpura-itp-therapeutics-market-analysis-by-product-corticosteroids-intravenous-immunoglobulin-anti-d-immunoglobulin-tpo-ra-and-segment-forecasts-to-2020

Further key findings from the study suggest:

TPO-RA is the most lucrative segment of this market and is expected to witness a surge in demand owing to the potential commercialization of Avatrombopag in 2015. Moreover, the ability of this class to cater to splenectomized patients witnessing relapses attributes to such rapid growth.

North America accounted for over 40% of the global ITP market revenue in 2013, on account of high market penetration rates and favorable regulations. Presence of an extensive number of clinical trial studies related to combination therapy and new product development is also expected to drive regional growth during the forecast period.

Europe was the second largest regional ITP therapeutics market in 2013 and is expected to maintain its position over the forecast period. High product usage rates and the presence of government initiatives granting special status to orphan drugs are some factors accounting for its large market share.

Read Sample report of this Category: http://www.radiantinsights.com/catalog/pharmaceutical

Asia Pacific is expected to present high future growth potential over the next six years, owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives and sophisticated healthcare infrastructure in Japan and Australia are also expected to attribute to its market attractiveness.

Key players of the ITP therapeutics market include GSK, Amgen Inc., Grifols Biologicals Inc., Eisai and F.Hoffman-La Roche.

Table of Contents

Chapter 1 Executive Summary

Chapter 2 ITP Therapeutics Industry Outlook

             2.1 Market Segmentation

             2.2 Market Size and Growth Prospects

             2.3 Market Dynamics

             2.3.1 Market Driver Analysis

             2.3.1.1 Presence of favorable government initiatives

             2.3.1.2 Growing demand for combination therapies and new product development

             2.3.1.3 Presence of co-existing conditions inducing ITP

See More Reports of This Category by Radiant Insights:

·         Australia Respiratory Disposables Market Outlook to 2021 - http://www.radiantinsights.com/research/australia-respiratory-disposables-market-outlook-to-2021

·         Australia Respiratory Measurement Devices Market Outlook to 2021 - http://www.radiantinsights.com/research/australia-respiratory-measurement-devices-market-outlook-to-2021

             2.3.2 Market Restraint Analysis

             2.3.2.1 Availability of external product substitutes

             2.3.2.2 Associated risks resulting in product withdrawal

             2.4 Key Opportunities Prioritized

             2.5 Industry Analysis - Porter's

             2.6 ITP Therapeutics - PESTEL Analysis

             2.7 Combination Therapy for ITP

             2.7.1 Combination of IVIG with oral corticosteroids

             2.7.1.1 IVIG With High Dose Methylprednisolone

             2.7.1.2 Combination of IVIG and prednisolone

             2.7.2 Combination of corticosteroids and monoclonal antibodies

             2.7.2.1 Dexamethasone with rituximab (Mabthera)

             2.7.2.2 Combination of rituximab with cyclophosphamide, vincristine and prednisone

             2.7.3 Combination of immunosuppressant therapy

             2.7.3.1 Combination of azathioprine, danzol or mycophenolate mofetil

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com  
Blog URL: http://www.radiantinsightsinc.blogspot.com